Younossi ZM - Search Results

1

Diagnosis and Management of Primary Biliary Cholangitis.

Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kim WR, Kowdley KV, Jacobson IM. Younossi ZM, et al. Am J Gastroenterol. 2019 Jan;114(1):48-63. doi: 10.1038/s41395-018-0390-3. Am J Gastroenterol. 2019. PMID: 30429590 Review.

2

The impact of liver disease on health-related quality of life: a review of the literature.

Martin LM, Sheridan MJ, Younossi ZM. Martin LM, et al. Among authors: younossi zm. Curr Gastroenterol Rep. 2002 Feb;4(1):79-83. doi: 10.1007/s11894-002-0041-z. Curr Gastroenterol Rep. 2002. PMID: 11825545 Review.

3

Non-alcoholic fatty liver disease: an overview.

Mulhall BP, Ong JP, Younossi ZM. Mulhall BP, et al. Among authors: younossi zm. J Gastroenterol Hepatol. 2002 Nov;17(11):1136-43. doi: 10.1046/j.1440-1746.2002.02881.x. J Gastroenterol Hepatol. 2002. PMID: 12453271 Review.

4

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ; Proactive Study Group. Afdhal NH, et al. Gastroenterology. 2004 May;126(5):1302-11. doi: 10.1053/j.gastro.2004.01.027. Gastroenterology. 2004. PMID: 15131791 Clinical Trial.

5

Hepatitis C with normal liver enzymes: to treat or not to treat. Pro: most patients should be treated.

Koff JM, Younossi Z. Koff JM, et al. Am J Gastroenterol. 2004 Jun;99(6):972-3. doi: 10.1111/j.1572-0241.2004.40510.x. Am J Gastroenterol. 2004. PMID: 15180709 Review. No abstract available.

6

Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.

Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, Martin LM, Assmann J, Gramlich T, Mullen KD, O'Shea R, Carey WD, Ferguson R. Younossi ZM, et al. J Clin Gastroenterol. 2004 Sep;38(8):705-9. doi: 10.1097/01.mcg.0000135372.10846.2a. J Clin Gastroenterol. 2004. PMID: 15319656

7

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH; PROACTIVE Study Group. Pockros PJ, et al. Hepatology. 2004 Dec;40(6):1450-8. doi: 10.1002/hep.20482. Hepatology. 2004. PMID: 15565613 Clinical Trial.

8

Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.

Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, Goodman Z, Younossi Z. Hossain N, et al. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1224-9, 1229.e1-2. doi: 10.1016/j.cgh.2009.06.007. Epub 2009 Jun 25. Clin Gastroenterol Hepatol. 2009. PMID: 19559819

9

Manifestations of chronic hepatitis C virus infection beyond the liver.

Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Jacobson IM, et al. Among authors: younossi zm. Clin Gastroenterol Hepatol. 2010 Dec;8(12):1017-29. doi: 10.1016/j.cgh.2010.08.026. Epub 2010 Sep 24. Clin Gastroenterol Hepatol. 2010. PMID: 20870037 Review.

10

Non-invasive markers for hepatic fibrosis.

Baranova A, Lal P, Birerdinc A, Younossi ZM. Baranova A, et al. Among authors: younossi zm. BMC Gastroenterol. 2011 Aug 17;11:91. doi: 10.1186/1471-230X-11-91. BMC Gastroenterol. 2011. PMID: 21849046 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

626 results

Search Page